Urinary Tract Infection Therapeutics Market 2018: Global Forecasts to 2023 - Segmented by Type of Drug and Indication - ResearchAndMarkets.com

DUBLIN--()--The "Global Urinary Tract Infection Therapeutics Market - Segmented by Type of Drug, and Indication - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global urinary tract infection therapeutics market is expected to register a CAGR of 3.5% during the forecast period 2018 to 2023.

According to World Health Organization (WHO), in 1980, there were 108 million people suffering from diabetes; this number increased to 422 million in 2014, while the prevalence of diabetes in adults increased from 4.7% in 1980 to 8.5% in 2014. This trend of increment in the prevalence rate of diabetes among adults is expected to continue during the forecast period. Therefore, with increasing prevalence, the number of UTI increases, and thus, the high demand for drugs. Hence, increasing prevalence of diabetes worldwide is expected to act as a major driver for the global urinary tract infection therapeutics market.

In addition, launch of combination drugs, which are more effective, and increasing geriatric population are also expected to boost the growth of the urinary tract infection therapeutics market.

North America dominates the urinary tract infection therapeutics market due to high UTI detection, along with increasing diabetes prevalence in the region. Europe is also expected to boost the UTI therapeutics market, owing to increased accessibility to healthcare facilities, along with high UTI prevalence among the population.

Key Developments in the Market

  • August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug, which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam.
  • December 2017: The F.D.A accepted the review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI, including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) in June, 2018.

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

  • Pfizer Limited
  • Boehringer Ingelheim
  • Bayer AG
  • Glaxosmithkline Plc
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Astrazeneca
  • Cipla Inc.
  • Merlion Pharma

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/8fj9pt/urinary_tract?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Urological Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs, Urological Disorders Drugs